摘要:
The invention is directed to processes for preparing 2-aminothiazole-5-carboxamides of formula I wherein R1, R2, R3, R4 and R5 are as defined as set forth in the specification herein.
摘要:
A novel process and intermediates thereof for making N-aryl pyridones of the type shown below from appropriate pyridinolates is described. These compounds are useful as intermediates for the synthesis of clinical candidates.
摘要:
The present invention relates to new, efficient processes for the preparation of 5-(2-oxazolylalkylthio)-2-azacycloalkanoylaminothiazole compounds of formula I or a pharmaceutically acceptable salt thereof, wherein: R is alkyl, aryl or heteroaryl; R1, R2, R3, R4 and R5 are each independently hydrogen, alkyl, aryl or heteroaryl; R6 and R7 are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy; R8 is hydrogen, alkyl, aryl, heteroaryl, CONR9R10, COR11 or COOR12; R9, R10, R11 and R12 are each independently hydrogen, alkyl or aryl; m equals 0 to 5; and n equals 0 to 5, which are novel, potent inhibitors of cyclin dependent kinases (cdks). The present invention further concerns new key intermediate compounds, a quaternary ammonium salt of formula III′ and a 2-oxazolylalkyl derivative of formula IX.
摘要翻译:本发明涉及制备式I的5-(2-恶唑基烷硫基)-2-氮杂环烷酰氨基噻唑化合物或其药学上可接受的盐的新的,有效的方法,其中:R是烷基,芳基或杂芳基; R 1,R 2 R 3,R 4和R 5各自独立地为氢,烷基,芳基或杂芳基; R 6和R 7各自独立地为氢,烷基,芳基,杂芳基,卤素 ,羟基或烷氧基; R 8是氢,烷基,芳基,杂芳基,CONR 9 R 10,COR 11或COOR 12; R 9,R 10,R 11 且R 12各自独立地为氢,烷基或芳基; m等于0至5; 和等于0至5,这是细胞周期蛋白依赖性激酶(cdks)的新型有效抑制剂。 本发明还涉及新的关键中间体化合物,式III'的季铵盐和式IX的2-恶唑基烷基衍生物。
摘要:
The present invention provides an improved process for the preparation of N-(substituted phenyl)-3-alkyl-, aryl- and heteroarylsulfonyl-2-hydroxy-2-alkyl- and haloalkylpropanamide compounds of formula I that exhibit antiandrogenic activity and are useful in the treatment of malignant or benign prostatic disease or of androgen dependent disease conditions such as acne, hirsutism or seborrhea.
摘要:
The present invention relates to new, efficient processes for the preparation of 5-(2-oxazolylalkylthio)-2-arylacetylaminothiazole compounds of formula I or a pharmaceutically acceptable salt thereof, wherein: R1, R2, R4, R5, R6, R8, R9, R12 and R13 are each independently hydrogen, alkyl, aryl or heteroaryl; R3, R7, R10 and R11 are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy; and X is CH or N, which are novel, potent inhibitors of cyclin dependent kinases (cdks). The present invention also concerns a new process for the preparation of formylarylacetates and formylarylacetic acids.
摘要翻译:本发明涉及制备式I的5-(2-恶唑基烷硫基)-2-芳基乙酰氨基噻唑化合物或其药学上可接受的盐的新的,有效的方法,其中:R1,R2,R4,R5,R6,R8,R9, R 12和R 13各自独立地为氢,烷基,芳基或杂芳基; R 3,R 7,R 10和R 11各自独立地为氢,烷基,芳基,杂芳基,卤素,羟基或烷氧基; 而X是CH或N,它们是细胞周期蛋白依赖性激酶(cdks)的新型有效抑制剂。 本发明还涉及制备甲酰芳基乙酸酯和甲酰芳基乙酸的新方法。
摘要:
The present invention provides a novel alpha-(N-sulfonamido)acetamide compound, its pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease and other conditions associated with β-amyloid peptide.
摘要:
The invention relates to processes for preparing compounds having the formula, and crystalline forms thereof, wherein Ar is aryl or heteroaryl, L is an optional alkylene linker, and R2, R3, R4, and R5, are as defined in the specification herein, which compounds are useful as kinase inhibitors, in particular, inhibitors of protein tyrosine kinase and p38 kinase.
摘要翻译:本发明涉及制备具有下式的化合物及其结晶形式的方法,其中Ar为芳基或杂芳基,L为任选的亚烷基连接基,R 2,R 3, R 4,R 5和R 5如本说明书中所定义,该化合物可用作激酶抑制剂,特别是蛋白酪氨酸激酶和p38激酶的抑制剂 。
摘要:
The present invention concerns an improved process of making d4T from 5-MU. Another aspect of the invention relates to useful intermediates produced during the process.